The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay by Habte, Habtom H. et al.
BioMed CentralVirology Journal
ssOpen AcceResearch
The role of crude human saliva and purified salivary MUC5B and 
MUC7 mucins in the inhibition of Human Immunodeficiency Virus 
type 1 in an inhibition assay
Habtom H Habte1, Anwar S Mall*1, Corena de Beer2, Zoë E Lotz1 and 
Delawir Kahn1
Address: 1Department of Surgery, University of Cape Town, Cape Town, South Africa and 2Discipline of Medical Virology, University of 
Stellenbosch and National Health Laboratory Service, Cape Town, South Africa
Email: Habtom H Habte - hhabte@uctgsh1.uct.ac.za; Anwar S Mall* - amall@uctgsh1.uct.ac.za; Corena de Beer - cdeb@sun.ac.za; 
Zoë E Lotz - zlotz@uctgsh1.uct.ac.za; Delawir Kahn - dkahn@uctgsh1.uct.ac.za
* Corresponding author    
Abstract
Background: Despite the continuous shedding of HIV infected blood into the oral cavity and the
detectable presence of the AIDS virus at a high frequency, human saliva is reported to inhibit oral
transmission of HIV through kissing, dental treatment, biting, and aerosolization. The purpose of
this study was to purify salivary MUC5B and MUC7 mucins from crude saliva and determine their
anti-HIV-1 activities.
Methods: Following Sepharose CL-4B column chromatography and caesium chloride isopycnic
density-gradient ultra-centrifugation, the purity and identity of the mucins was determined by SDS-
PAGE and Western blotting analysis respectively. Subsequently an HIV-1 inhibition assay was
carried out to determine the anti-HIV-1 activity of the crude saliva and purified salivary mucins by
incubating them with subtype D HIV-1 prior to infection of the CD4+ CEM SS cells.
Results: Western blotting analysis confirmed that the mucin in the void volume is MUC5B and the
mucin in the included volume is MUC7. The HIV inhibition assay revealed that both the crude saliva
and salivary MUC5B and MUC7 mucins inhibited HIV-1 activity by 100%.
Conclusion: Although the mechanism of action is not clear the carbohydrate moieties of the
salivary mucins may trap or aggregate the virus and prevent host cell entry.
Background
Several studies have shown that the human immunodefi-
ciency virus (HIV) is not transmitted via the oral route [1].
It has also been reported that there is a continuous shed-
ding of HIV infected blood into the oral cavity from
mucosal and gingival lesions in HIV-infected patients,
resulting in the detectable presence of the acquired immu-
nodeficiency syndrome (AIDS) virus at a high frequency
in the oral cavity [2-6]. However, several epidemiological
studies have failed to present any conclusive evidence
about oral transmission of HIV through kissing, dental
treatment, biting, and aerosolization [7-14].
Published: 24 November 2006
Virology Journal 2006, 3:99 doi:10.1186/1743-422X-3-99
Received: 01 September 2006
Accepted: 24 November 2006
This article is available from: http://www.virologyj.com/content/3/1/99
© 2006 Habte et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
Virology Journal 2006, 3:99 http://www.virologyj.com/content/3/1/99Extensive studies have been carried out after the initial
findings of Fultz [1] that human saliva inhibited the activ-
ity of the AIDS virus [8,15,16]. These studies showed that
the anti-HIV activity appeared to be highest in sub-man-
dibular secretions and whole saliva rather than parotid
secretions [2,3,11,17-19]. Although most of these studies
suggested that HIV-1 particles were aggregated by high-
molecular weight components (of mucus) in both whole
saliva and specifically in sub-mandibular/sublingual
secretions, and which were removable by filtration
through 0.45 μm pore filter [3,8,17,20,21], there has been
no detailed analysis to identify the mucin components of
these secretions and determine which of these compo-
nents displays HIV inhibitory activity.
Thus far five secreted gel-forming (MUC2, MUC5AC,
MUC5B, MUC6 MUC19), three secreted non gel-forming
(MUC7, MUC8, MUC9), ten membrane bound (MUC1,
MUC3A, MUC3B, MUC4, MUC11, MUC12, MUC13,
MUC16, MUC17, MUC20) and three unclassified mucins
(MUC14, MUC15, MUC18) have been identified [22].
Human saliva is known to contain, amongst many other
factors two types of mucins, namely MUC5B and MUC7
[23], and more recently MUC19 [24]. The aim of this
study was to isolate and purify these mucins in the saliva
and to determine their anti-HIV-1 activity individually.
In its special report on HIV and AIDS on 30 May 2006,
UNAIDS stated that since its outbreak in 1981, AIDS was
found to be responsible for the deaths of more than 25
million people world-wide, with 2.8 million deaths and
over 4.1 million new infections in 2005 alone [25]. This
report estimated that there were more than 38.6 million
HIV positive people world-wide at the end of 2005, of
which two-thirds of those infected lived in Sub-Saharan
Africa. Of these, South Africa with 27.9% of its adult pop-
ulation living with HIV [26] remains one of the worst
affected countries in the world [27]. This epidemic is
expected to cost South Africa 17 % of its GDP growth by
2010 [26]. With this in mind, the present study could
make a significant contribution to the efforts being made
in controlling this epidemic.
In this study we report the anti-HIV-1 activities of human
crude saliva and purified salivary MUC5B and MUC7
mucins in an in vitro inhibition assay. We have shown that
both crude saliva and purified MUC5B and MUC7 mucins
inhibit HIV-1 activity by 100% in the range from 900 μg
to 0.09 μg mucin concentration.
Materials and methods
Ethics
The University of Cape Town Research and Ethics Com-
mittee approved this study (ethics approval number REC
REF: 283/2004).
Materials
The ECL™ Western Blotting Detection Kit was from Amer-
sham Biosciences (Amersham UK). Nitrocellulose mem-
brane and dialysis tubing were from Kimix (chemical and
laboratory suppliers, SA). Polyclonal rabbit anti-MUC5B
(Lum 5B-2), goat anti-MUC7, goat anti-rabbit and rabbit
anti-goat horse radish peroxidise (HRPO) linked second-
ary antibodies were from Santa Cruz Biotechnology, Inc
(Santa Cruz, California). The CD4+ CEM SS cells were
from AIDS Research and Reference Reagent Programme
(Germantown, USA). RPMI 1640, L-Glutamine and heat-
inactivated fetal bovine serum were from Gibco (Massa-
chusetts, USA). IL-2 and p24 antigen kit were from Roche
Diagnostics (Germany) and Vironostika HIV-1 Antigen
kit Biomérieux (France) respectively. Sepharose CL-4B
and reagent solvents such as guanidinium chloride
(GuHCl), phenylmethylsulfonylfluoride (PMSF), cae-
sium chloride (CsCl), ethylenediaminetetra-acetic acid
disodium salt (Na2-EDTA), N-ethylmaleimide (NEM),
and 3-((3-cholamidopropyl)-dimethyl-ammonio)-1-pro-
pane-sulfonate (CHAPS) were from Sigma (UK). Trypan
Blue Dye solution was from Merck (Germany).
Saliva collection
Saliva was collected from healthy symptom free 'normal'
female and male volunteers (who declared a risk-free life-
style) from the laboratory who abstained from eating and
drinking for at least 2 h prior to collection. Whole saliva
was stimulated by chewing on parafilm and collected into
6 M GuHCl containing a spectrum of protease inhibitors
(10 mM EDTA, 5 mM NEM, 1 mM PMSF) and 0.1%
CHAPS pH 6.5. Samples were collected on ice and then
stored at -20°C.
Sepharose CL-4B gel filtration
Crude salivary mucus was solubilised by overnight mixing
at 4°C on a revolving rotor. The insoluble debris was then
separated from the soluble mucus by centrifugation at
4400 g for 10 min at 4°C.
Aliquots of the supernatant (20 ml) were chromato-
graphed on a Sepharose CL-4B gel filtration column equil-
ibrated and eluted with 4 M GuHCl containing 10 mM
EDTA, 5 mM NEM and 0.05% CHAPS at pH 6.5 and at a
flow rate of 48 ml/h at room temperature. Following PAS
and protein (A280) assays, the void (Vo) and included vol-
ume (Vi) materials were pooled separately, dialysed
against three changes of distilled water at 4°C and freeze-
dried.
Mucin preparation
For the HIV inhibition assay, crude saliva was collected
into 0.1 M Tris-HCl, 2% (w/v) EDTA and 5 mM PMSF pH
7.5 (saliva:buffer ratio 1:2). After solubilisation by over-
night mixing at 4°C on a revolving rotor, the insolublePage 2 of 12
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min at 4°C. The supernatant was then dialysed over three
changes of distilled water at 4°C and freeze-dried.
The mucin that eluted in the included volume (Vi) of the
column was subjected to caesium chloride isopycnic den-
sity-gradient ultra-centrifugation, twice for 48 h at a 105
000 g and 4°C in a Beckman L45 ultra-centrifuge [28].
Briefly, Vi samples dissolved in 4 M GuHCl containing a
cocktail of proteolytic inhibitors (as described above)
were adjusted to a density of 1.39 to 1.40 g/ml with cae-
sium chloride prior to centrifugation. Mucin rich fractions
were pooled, dialysed against three changes of distilled
water at 4°C and freeze-dried.
SDS-PAGE
SDS-PAGE was carried out according to the method of
Laemmli [29] in a buffer containing 0.2% SDS using 4%
(w/v) stacking gels and 10% separating gels [30,31], in a
Hoefer Mighty Small mini-electrophoresis system. Sam-
ples were prepared in reducing gel loading buffer contain-
ing 2% SDS, 10% glycerol, 0.01% bromophenol blue and
5% mercaptoethanol and boiled for 2 min prior to load-
ing. After electrophoresis gels were stained for carbohy-
drate with PAS [32] and for protein with Coomassie
Brilliant Blue G-250.
Western blotting
After gel electrophoresis mucins were transferred to a
nitrocellulose membrane (Nitrocellulose, 0.22 Micron)
using a semi-dry electroblotting unit at 0.8 mA/cm2. The
transfer buffer used contained 192 mM glycine, 25 mM
Tris, 1.3 mM SDS and 20% (v/v) methanol. After electro-
blotting non-specific binding was blocked by incubating
the membranes overnight in 5% (m/v) low fat milk pow-
der in TBS, 0.05% Tween-20 (TBST) at 4°C. The mem-
branes were then washed with TBST for 3 × 5 min and
incubated for 2 h with rabbit anti-MUC5B and goat anti-
MUC7 polyclonal antibodies diluted in 5% (m/v) low fat
milk powder in TBST at 1:500 and 1:100 dilutions respec-
tively. The membranes were washed for 3 × 5 min with
TBST and incubated for 1 h with HRPO linked secondary
antibodies (goat anti-rabbit and rabbit anti-goat) diluted
in 5% (m/v) low fat milk powder in TBST at 1:5000 dilu-
tion. After another TBST wash (3 × 5 min) bands that
interacted with the antibodies were detected by exposing
the membrane to ECL detection.
Amino acid analysis
The amino acid contents of purified MUC5B and MUC7
mucins were analysed using a high pressure liquid chro-
matography (HPLC) system. The analysis procedure was
similar to that of Klapper [33] and Cohen and Strydom
[34]. The samples were vacuum-dried and placed in a
hydrolysis vessel containing some constant boiling HCl
and 1% (v/v) phenol. The vessel was cleaned with nitro-
gen gas and sealed under vacuum. The samples were then
hydrolysed in the gas phase at 110°C for 24 h. Following
hydrolysis, the vials were cooled and vacuum dried to
remove the residual HCl. The dried samples were re-dis-
solved in citrate buffer pH 2.2 and injected into a HPLC
column from Waters Associates, Medford, MA., packed
with a cation exchange resin (sulfonated polystyrene
cross-linked with divinylbenzene) and eluted with a series
of buffers ranging from a low (0.25 M trisodium citrate,
pH 3.05) to high (0.25 M sodium nitrate, pH 9.5) pH.
Detection was carried out using post column derivatiza-
tion with o-phthalaldehyde (OPA), a fluorescent reagent
that reacts with all the amino acids except proline. The rel-
ative ratios of the individual amino acids for each sample
was determined and compared to each other. For proline
detection samples were treated with sodium hypochlorite
prior to post column derivatization with o-phthalalde-
hyde (OPA).
Toxicity assay
The toxicity of crude saliva and purified salivary MUC5B
and MUC7 mucins to the CD4+ CEM SS cells was deter-
mined by a toxicity assay. Briefly, 500 μl of the CD4+ CEM
SS cells in RPMI complete containing 10% Fetal Calf
Serum, 1% Penicillin/Streptomycin antibiotic, 10 μmol
Fungin and 50 μmol 2-mercaptoethanol (final concentra-
tion 2.5 × 106 cells/ml) was incubated with 250 μl of IL-2
and 250 μl (0.9 mg) of crude saliva or purified salivary
MUC5B and MUC7 mucins in a CO2 incubator for 24 h.
As controls CEM SS cells with IL-2 only and IL-2 without
CEM SS cells (blank) were used. After spinning at
1400rpm for 5 min, cells were re-suspended in 500 μl of
RPMI and live and dead cells were counted using Trypan
blue exclusion criteria. The percentage of viable cells was
calculated as live cells/total cells × 100.
Inhibition assay
The anti-HIV-1 activities of crude saliva and purified sali-
vary MUC5B and MUC7 mucins were tested in an inhibi-
tion assay according to the method of Nagashunmugam et
al. [3]. Briefly, the crude saliva and purified salivary
MUC5B and MUC7 mucins were dissolved in 0.25% PBS
and (500 μl or 0.9 mg each) were mixed with 4 ml of the
subtype D HIV-1 supernatant fluid (SNF) and incubated
for 60 min at 37°C. As controls heat inactivated HIV-1
and HIV-1 plus media (RPMI 1640 with 10% fetal calf
serum and IL-2) were used. The virus was first isolated
from an AIDS patient by the Department of Medical Virol-
ogy, Tygerberg Hospital, University of Stellenbosch, in
February 1986, and it was fully characterised and
sequenced subsequently. At the end of the incubation
period the mixtures (virus plus mucins) and the control
(virus plus media) were filtered through 0.45 μm pore size
cellulose acetate filter (25 mm diameter), and both thePage 3 of 12
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CEM SS cells at 37°C at a concentration of 0.5 × 106 cells/
ml for 30 min, 1 h and 3 h. Cells were then washed three
times with PBS to remove free virus and cultured. Super-
natant fluid was harvested on Day 4 and viral replication
was measured by a qualitative p24 antigen assay. End-
points were calculated by the Reed-Muench formula and
the 50% tissue culture infective dose (TCID50) was
expressed as the highest dilution that produced a positive
qualitative p24 antigen result. All samples were done in
triplicate and the anti-HIV-1 activity of each mucin was
tested in a serial tenfold dilution (10-1 to 10-4).
Results
Sepharose CL-4B gel filtration
Sepharose CL-4B gel filtration demonstrated that saliva
contains two species of carbohydrate-rich mucin macro-
molecules which are distinguishable according to their
size. Of these two populations, the glycoprotein (MG1)
was excluded in the void volume (Vo) [23] and the glyco-
protein (MG2) in the included volume (Vi) of the gel fil-
tration column [23] (Fig. 1). A sharp PAS positive peak
was seen eluting in the void volume and a broader peak in
the included volume of the column, which was alongside
a protein positive peak. The protein peak that eluted in the
void volume, coinciding with the PAS positive peak, was
much smaller.
SDS-PAGE
To check the purity of the materials eluted in the Vo and
the Vi of the gel filtration column, fractions eluting under
these peaks were pooled separately, dialysed extensively
against distilled water, freeze-dried and subjected to 10%
SDS-PAGE and stained for protein with Coomassie Bril-
liant Blue G-250 (Fig. 2a and 3a) and for carbohydrate
with PAS (Fig. 2b and 3b).
The PAS positive void volume material gave a strong band
sitting on the top of the stacking and running gels, very
characteristic of the electrophoretic behaviour of large-
sized mucins (Fig. 2b) [30]. On the other hand the mate-
rial that eluted in the Vi showed a prominent band of
greater electrophoretic mobility and of relatively smaller
size than Vo mucin, in that the mucins slightly entered the
running gel (Fig. 3b). Also there were a range of fainter
bands ranging in size from 66–30kDa (Fig. 3b, lanes 1–3
and 5 and 6). More contaminant protein associated with
mucin was present in the Vi peak (Fig. 3a) than the Vo peak
(Fig. 2a) suggesting the need for further purification of the
material that eluted in the included volume of the col-
umn.
Mucin purification
Material that eluted in the included volume of the gel fil-
tration column was subjected to density-gradient ultra-
centrifugation in caesium chloride. Mucin rich fractions
from the first density gradient (Fig. 4a) were pooled and
subjected to a second spin in caesium chloride (Fig. 4b),
after which the mucin rich fractions were pooled, dialysed
against distilled water and freeze-dried. SDS-PAGE analy-
sis of these mucins showed less protein contaminant (Fig.
5, lane 2), except for low molecular weight material of
30kDa and under. As indicated by the arrows, the PAS
stain of the same material gave two prominent bands in
the region of 220kDa and 46–60kDa (Fig. 5, lane 3).
Traces of material were also seen at 21.5kDa and under
(Fig. 5, lane 3).
Western blotting
To determine the identity of the Vo and Vi mucins from the
gel filtration column material eluting under these peaks
was subjected to 10% SDS-PAGE and then transferred to
nitrocellulose membrane and probed with rabbit anti-
MUC5B and goat anti-MUC7 polyclonal antibodies
respectively. The results showed that the Vo material sit-
ting on the top of the gel is MUC5B (Fig. 6a, lanes 2 and
3) and the two bands slightly entered the running gel that
interacts with the anti-MUC7 polyclonal antibody are the
two glycoforms of MUC7 (Fig. 6b, lane 3). The two glyco-
forms of MUC7 in Figure 6b are indicated by arrows.
Amino acid analysis
Following the amino acid analysis (Table 1) both MUC5B
and MUC7 mucins were found to contain higher amounts
of threonine, serine, glutamic acid, glycine and aspartic
acid. However, the amount of threonine in MUC7 is very
low. Of these signature amino acids of mucins, serine,
threonine, and proline were found to comprise 26% and
28% of the MUC5B and MUC7 mucins respectively.
Toxicity assay
Prior to the HIV inhibition assay the toxicity of the crude
saliva and purified salivary MUC5B and MUC7 mucins to
the CD4+ CEM SS cells was determined by toxicity assay.
Based on this assay (data not shown) no cell death or tox-
icity of these mucins to the CD4+ CEM SS cells was
detected.
Inhibition assay
Subsequent to the toxicity assay the anti-HIV-1 activities
of the crude saliva and purified salivary MUC5B and
MUC7 mucins were determined by HIV inhibition assay.
The result revealed that after a 30 min incubation period
during which the mixtures three separate mixtures (HIV-1
plus crude saliva), (HIV-1 plus MUC5B) and (HIV-1 plus
MUC7) were incubated with the CD4+ CEM SS cells, no
HIV-1 infection of these cells was observed (Fig. 7). Simul-
taneously, to determine the effect of the incubation
period between the CD4+ CEM SS cells and the mixtures
described above on the infectivity of these cells, incuba-Page 4 of 12
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Sepharose CL-4B gel filtration of crude salivaFigure 1
Sepharose CL-4B gel filtration of crude saliva. An aliquot (20 ml) of soluble human crude saliva extracted in 6 M GuHCl con-
taining 10 mM EDTA, 5 mM NEM, 1 mM PMSF and 0.1% CHAPS pH 6.5 was chromatographed and eluted with 4 M GuHCl 
containing 10 mM EDTA, 5 mM NEM and 0.05% CHAPS pH 6.5 at flow rate of 48 ml/h at room temperature. Fractions were 
analysed for carbohydrate with PAS at 555 nm () and for protein A280 (■). Materials eluted in the void volume (Vo) and 
included volume (Vi) were pooled separately, dialysed against three changes of distilled water for overnight at 4°C and freeze-
dried.
SDS-PAGE analysis of the salivary mucus eluted in the Vo of the Sepharose CL-4B gel filtration columnFigure 2
SDS-PAGE analysis of the salivary mucus eluted in the Vo of the Sepharose CL-4B gel filtration column. Freeze-dried material 
(30 μg) of the Vo prepared in reducing gel loading buffer was separated by 10% SDS-PAGE and stained with Coomassie Brilliant 
Blue G-250 (a) and PAS (b). The molecular weight marker is indicated by Mw and lanes 1 to 6 represents samples from 6 
donors.
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Caesium chloride isopycnic density-gradient ultra-centrifugation of the material eluted in the Vi of the gel filtration columnFigure 4
Caesium chloride isopycnic density-gradient ultra-centrifugation of the material eluted in the Vi of the gel filtration column. 
Freeze-dried material eluted in the Vi was dissolved in 4 M GuHCl containing 10 mM EDTA, 5 mM NEM and 0.05% CHAPS pH 
6.5 and adjusted to a density of 1.39 to 1.40 g/ml with caesium chloride. Density gradient centrifugation was performed in a 
Beckman L45 ultra-centrifuge for 48 h at 105 000 g at 4°C. Fractions with high PAS () and low protein (Lowry) (■) (a) were 
pooled and adjust to a density of 1.39 to 1.40 g/ml with caesium chloride for a second step centrifugation (b). Mucin rich frac-
tions with a density (▲) between 1.37–1.42 were pooled, dialysed against three changes of distilled water for overnight at 4°C 
and freeze-dried.
SDS-PAGE analysis of the salivary mucus eluted in the Vi of the Sepharose CL-4B gel filtration columnFigure 3
SDS-PAGE analysis of the salivary mucus eluted in the Vi of the Sepharose CL-4B gel filtration column. Freeze-dried material 
(30 μg) of the Vi prepared in reducing gel loading buffer was separated by 10% SDS-PAGE and stained with Coomassie Brilliant 
Blue G-250 (a) and PAS (b). The molecular weight marker is indicated by Mw and lanes 1 to 6 represents samples from 6 
donors.
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No difference in the rate of inhibition due to time differ-
ences was detected (Fig. 7). Serial tenfold dilution (10-1 to
10-4) of the mucins was also done to determine the anti-
HIV-1 activity of these mucins at the highest dilution. All
the mucins showed anti-HIV-1 activity down to the con-
centration of 0.09 μg or in the range of 900 μg to 0.09 μg
(data not shown).
In the controls, where the virus was incubated with the
media only, prior to addition to the CD4+ CEM SS cells at
all time points (30 min, 1 h and 3 h), 100% of HIV-1 rep-
lication or infection of the CD4+ CEM SS cells was
detected (Fig. 7). However no HIV-1 infection was
revealed when heat inactivated HIV-1 was used (Fig. 7).
To determine whether the HIV-1 activity of the crude
saliva and purified salivary MUC5B and MUC7 mucins is
by aggregation or trapping of the virus, the mixtures (HIV-
1 plus crude saliva), (HIV-1 plus purified salivary
MUC5B), (HIV-1 plus purified salivary MUC7) and (HIV-
1 plus media), at the end of the 60 min incubation period,
were filtered through 0.45 μm pore size cellulose acetate
filter (25 mm diameter) and the filtrates were incubated
with the CD4+ CEM SS cells at all time-points (30 min, 1
h and 3 h). While 100% of viral replication or infection of
the CD4+ CEM SS cells was detected with the filtrate of the
control (HIV-1 plus media) (Fig. 8), no HIV-1 replication
or infection of the CD4+ CEM SS cells was detected when
the filtrates from the three mixtures were used (Fig. 8).
Discussion
In the present study human crude saliva was separated by
Sepharose CL-4B gel filtration column into material elut-
ing as two major PAS positive peaks in the void (MG1)
and included (MG2) volumes respectively and the mate-
rial under each peak identified as MUC5B and MUC7
respectively, confirming previous findings of Thornton et
al [23]. Amino acid analysis further supported this mate-
rial to be mucin [35]. The small protein peak that eluted
in the void volume of the gel filtration column, under the
large excluded PAS positive peak is very likely the protein
moiety of MUC5B (Fig. 1) [31]. The elution of the larger
protein peak, which begins under the included volume
(Vi) PAS positive peak and elutes nearer the total volume
of the column suggests that gel filtration was partially but
not entirely successful in removing a considerable amount
of protein contaminant from the crude saliva. SDS-PAGE
analysis of the PAS positive Vi peak material, when stained
for protein with Coommassie Blue, still showed protein
contamination of MUC7 (Fig. 2c). This material was
therefore further purified by caesium chloride density gra-
dient ultra-centrifugation.
To avoid any possible endogenous enzymatic degrada-
tion, sample analysis was carried out in 6 M GuHCl con-
taining protease inhibitors such as EDTA, NEM, and
PMSF. According to the report by Carlstedt et al. [36]
while PMSF and EDTA inhibit serine and metallo-pro-
teases respectively, NEM which inhibits thiol proteases is
reported to reduce disulfide bond formation between
mucins and non-mucinous components of the saliva by
blocking the free thiol groups on mucins.
Salivary mucins are known to bind with the non-muci-
nous components of the saliva such as amylase, lysozyme,
proline-rich protiens, statherin, histatins, SIgA and lactof-
errin which may change their physicochemical properties
[37-39]. As reported by Mehrotra et al. [40] and Zalewska
et al. [41] the hydrophobic regions of mucins are respon-
sible for these complex formations as well as for their
sticky characters. As a result mucins may stick to gels and
dialysis tubes during the purification and dialysis proc-
esses. Therefore in the present study CHAPS a detergent
was included in the chromatography buffer to minimize
the sticky characteristic and prevent loss of mucins during
dialysis and column chromatography [42].
SDS-PAGE analysis of the purified Vi materialFigure 5
SDS-PAGE analysis of the purified Vi material. After purifica-
tion, mucins were loaded onto a 10% SDS-PAGE and stained 
with Coomassie Brilliant Blue G-250 (lane, 1 and 2) and PAS 
(lane, 3). Molecular weight markers and the two mucin iso-
forms are indicated by lane 1and the arrows respectively.Page 7 of 12
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typical of mucins which, because of their large size, appear
at the top of the stacking and running gels (Fig. 2b and 3b,
and Fig 5, lane 3) [31,43,44]. The MUC7 mucin showed
two bands on SDS-PAGE (Fig 5, lane 3) and Western Blot-
ting (Fig. 6b, lane 3). This result agreed with that of Reddy
et al. [45], Mehrotra et al. [40] and Bolscher et al. [42],
which revealed the presence of two isoforms of MUC7,
designated MUC7a and MUC7b in saliva. According to
these authors the two isoforms have an identical amino
acid composition but a different glycosylation pattern
with respect to sialic acid and fucose. In the case of
MUC5B, although SDS-PAGE analysis revealed the pres-
ence of two closely situated mucin bands on the top of the
gel (Fig. 2b), Western blotting gave just one band (Fig. 6a,
lanes 2 and 3), again at the top of the membrane.
The amino acid analysis has shown the presence of higher
amounts of threonine, serine, glycine, glutamic acid, and
aspartic acid in salivary MUC5B and MUC7 mucins. This
agreed with the findings of Tabak et al. [46] that, mucins
contain large amounts of serine, threonine, proline,
Western blotting analysis of Vo and Vi material from the gel filtration column using rabbit anti-MUC5B and goat anti-MUC7 polyclonal an ibodiesFigure 6
Western blotting analysis of Vo and Vi material from the gel filtration column using rabbit anti-MUC5B and goat anti-MUC7 
polyclonal antibodies. a) Lanes 1, MUC7 (negative control), 2 and 3, Vo material from two donors and 4, respiratory MUC5B 
(positive control) and in b) Lanes 1, crude saliva (positive control), 2, gastric mucin (negative control) and 3, purified Vi material 
were separated by 10% SDS-PAGE and transferred to nitrocellulose membrane. Following overnight blocking, the membranes 
were incubated for 2 h with rabbit anti-MUC5B (a) and goat anti-MUC7 (b) polyclonal antibodies. Membranes were then incu-
bated for 1 h with goat anti-rabbit (a) and rabbit anti-goat (b) HRPO linked secondary antibodies and bands that interacted 
with the antibodies were detected by exposing the membrane to ECL detection. The arrows indicate the two glycoforms of 
MUC7.Page 8 of 12
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methionine in a very small amount also agreed with that
of Thomsson et al. [47]. Strangely enough threonine pre-
sented in smaller amount than the expected value espe-
cially in MUC7. According to Mehrotra et al. [40], this
could be due to the level of oligosaccharide substitution
of this residue.
It has been shown that the incubation of HIV with human
whole and submandibular saliva leads to a decrease in
viral infectivity and that this inhibition is considerably
reduced upon filtration of the saliva [11,15,18]. These
observations suggest that saliva-induced viral aggregation
serves to clear the virus from the oral cavity and lessen the
possibility of oral transmission [11]. It has also been sug-
gested that the most likely candidate in the oral defence
against AIDS is a macromolecular component [9], specif-
ically the mucus component of oral secretions [2].
Although these researchers speculated that crude saliva
[8], MUC5B and MUC7 [2], two of the known mucins in
saliva [23] are potentially involved in inhibition through
the entrapment of virus particles, a definitive attempt to
purify, identify and individually test these purified mucins
from saliva, against the AIDS virus, has not been done.
Although the HIV-1 Subtype C virus is currently the most
prevalent in South Africa, the Subtype D which was used
in this study was found during the early HIV epidemic in
South Africa and is still prevalent in the country, although
less frequently. Although we would very much have liked
to use the Subtype C strain, unfortunately, the Subtype D
is the only laboratory adapted strain available for an in
vitro HIV assay, in the entire country. As described in the
methods, this virus was first isolated from an AIDS patient
Inhibition of HIV-1 activity by human crude saliva and purified salivary MUC5B and MUC7 mucinsFigure 7
Inhibition of HIV-1 activity by human crude saliva and purified salivary MUC5B and MUC7 mucins. Crude saliva and purified sal-
ivary MUC5B and MUC7 mucins (0.9 mg each) were incubated with subtype D HIV-1 for 60 min and filtered through 0.45 μm 
pore size cellulose acetate filter. As controls HIV-1 treated with media and heat inactivated HIV-1 were used. The unfiltered 
samples were then incubated with CD4+ CEM SS cells at a concentration of 0.5 × 106cells/ml for 30 min, 1 h and 3 h. After PBS 
wash cells were cultured and viral replication was measured by a qualitative p24 antigen assay.
Table 1: Amino acid composition of MUC5B and MUC7 mucins.
Amino acids MUC5B (mole %) MUC7 (mole %)
Aspartic acid 8.9 9.1
Threonine 10.0 4.0
Serine 7.4 5.5
Glutamic acid 9.0 12.4
Proline 8.5 18.6
Glycine 9.0 14.4
Alanine 6.6 3.9
Valine 6.4 4.2
Methionine 1.6 1.7
Isoleucine 4.0 2.9
Leucine 7.6 4.7
Tyrosine 3.2 1.7
Phenylalanine 3.8 1.9
Lysine 4.6 4.7
Histidine 4.4 3.9
Arginine 4.0 5.6Page 9 of 12
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Virology Journal 2006, 3:99 http://www.virologyj.com/content/3/1/99by the Department of Medical Virology, Tygerberg Hospi-
tal (Cape Town, South Africa) in February 1986, and fully
characterised and sequenced subsequently. Simultane-
ously the T cell lines, CEM-SS cells which were used in this
experiment are known to produce distinct and repeatable
syncytia formation when infected with HIV-1. As reported
by Nara et al. [48], following the addition of HIV-1, these
cells develop easily quantifiable syncytia formation in
four to six days.
In this study we have demonstrated that when the HIV-1
was incubated with the crude saliva and purified salivary
MUC5B and MUC7 mucins and subsequently added to
the CD4+ CEM SS cells no viral replication or infection of
the CEM SS cells was detected by the p24 antigen assay.
However, when the HIV-1 was incubated with media
instead (as control), 100% infection of the CD4+ CEM SS
cells was detected. A possible explanation of the findings
of this study is that when mucins are incubated with HIV,
the mucins trap or aggregate the virus, leaving it entangled
in the mucin mesh which is retarded by filtration through
a 0.45 μm pore cellulose acetate filter [3,8,17,20,21], thus
preventing the virus from entering the host cells.
To prove this hypothesis we filtered the mixtures (HIV-1
plus crude saliva), (HIV-1 plus MUC5B), (HIV-1 plus
MUC7) and the control (HIV-1 plus media), at the end of
the incubation period, through a 0.45 μm pore size cellu-
lose acetate filter, and added the filtrates to the CD4+ CEM
SS cells. The filtrates from each of the mixtures failed to
infect the CD4+ CEM SS cells, as shown by the absence of
measurable p24 activity. This suggested that the mucins
aggregated all the viruses, hence leaving no free viruses in
the filtrates to cause viral infection. However, the filtrates
from the control (HIV-1 plus media) where mucins are
absent, gave 100% HIV-1 replication or infection of the
CEM SS cells. Therefore the media, unlike the mucins
failed to aggregate the viruses, resulting in free viruses in
the filtrate, which were then infective to the CD4+ CEM SS
cells.
Although the inhibition of HIV-1 by mucins is thought to
be by aggregation of the virus prior to host cell entry
[3,8,11,18], the specificity of this aggregation is not at all
clear. The findings by Fox et al. [9] and Nagashunmugam
et al. [3], which demonstrated low or no potency of saliva
against herpes simplex virus (HSV), HIV-2, simian immu-
nodeficiency virus, Epstein-Barr virus, cytomegalovirus,
hepatitis B virus and adenovirus implies that the specific
aggregation of HIV-1 by saliva or purified mucins could
require some specificity. One other possibility is that the
negative charges on mucins through sialic acid and sul-
phate groups [35] could be responsible for specific inter-
actions with receptors on the virus.
Inhibition of HIV-1 activity by human crude saliva and purified salivary MUC5B and MUC7 mucinsFigure 8
Inhibition of HIV-1 activity by human crude saliva and purified salivary MUC5B and MUC7 mucins. Crude saliva and purified sal-
ivary MUC5B and MUC7 mucins (0.9 mg each) were incubated with subtype D HIV-1 for 60 min and filtered through 0.45 
μpore size cellulose acetate filter. As controls HIV-1 treated with media and heat inactivated HIV-1 were used. The filtrates of 
the mixtures were then incubated with CD4+ CEM SS cells at a concentration of 0.5 × 106cells/ml for 30min, 1h and 3h. After 
PBS wash cells were cultured and viral replication was measured by a qualitative p24 antigen assay.Page 10 of 12
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Virology Journal 2006, 3:99 http://www.virologyj.com/content/3/1/99This study has shown that mucus and mucins have protec-
tive properties against the HI virus in certain situations.
More light needs to be shed on these processes to under-
stand further the role of mucins against infection to be
able to design further studies that will investigate the sig-
nificance of mucins in HIV-AIDS.
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